Charles River now has the ability to track and identify behavior in individual animals that are group- or single-housed, twenty-four hours a day for up to six months.
Charles River is proud to announce that we have recently become a Sustaining Member of the European Association for Cancer Research (EACR).
Charles River has acquired Sunrise Farms, Inc. from Elanco Animal Health (a division of Eli Lilly and Company). Sunrise is a US company based in Catskill, New York, dedicated to the production and supply of specific pathogen-free (SPF) chicken eggs for vaccine manufacturing and biomedical research.
Charles River has adopted and modified nonradioactive chromogenic in situ hybridization (CISH) methods that facilitate sensitive detection of RNA expression in tissues from multiple species.
During this event, hundreds of conference attendees, plus AACR CEO Dr. Margaret Foti, left their handprint on a canvas wall in support of Charles River’s fundraiser for the AACR Foundation. Thanks to this fantastic response, we were able to contribute over $3500 toward advancing cancer research.
In case you missed us at the Workshop on Recent Issues in Bioanalysis, you can now download our scientists’ poster presentations and read our latest blog detailing our co-chaired session at the Global CRO Council (GCC) Forum for Bioanalysis.
We are pleased to welcome Dr. Andreas Lazaros Chryssafidis, DVM, DSc, to our Ireland facility staff. Dr. Chryssafidis has an extensive background in veterinary parasitology and the conduct of animal clinical trials, and brings more than 12 years of expertise to the Charles River team.
Dr. Kurt Sales has joined the team in Edinburgh as the new Head of Immunology. He brings a wealth of knowledge from both his academic and commercial experience to support clients.
Charles River recently validated a novel Chronic Social Defeat assay in mice. By exposing mice to an aggressive mouse, we can induce a depressive phenotype that is measured using multiple endpoints.
Science Translational Medicine recently published a paper describing a new potential drug target (ATM kinase) for the orphan indication Huntington’s disease.